Provided by Tiger Fintech (Singapore) Pte. Ltd.

Qualigen Therapeutics, Inc.

3.53
+0.29008.95%
Post-market: 3.530.00000.00%17:39 EDT
Volume:9.72K
Turnover:33.05K
Market Cap:2.60M
PE:-0.08
High:3.53
Open:3.21
Low:3.20
Close:3.24
Loading ...

Company Profile

Company Name:
Qualigen Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
1996
Employees:
4
Office Location:
5857 Owens Avenue,Suite 300,Carlsbad,California,United States
Zip Code:
92008
Fax:
- -
Introduction:
Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

Directors

Name
Position
Michael Poirier
Chairman and Chief Executive Officer
Ira E. Ritter
Director
Kurt Kruger
Director
Matthew Korenberg
Director
Richard David
Director
Sidney Emery, Jr.
Director

Shareholders

Name
Position
Michael Poirier
Chairman and Chief Executive Officer
Christopher Lotz
Chief Financial Officer, Vice President of Finance
Tariq Arshad
Chief Medical Officer and Senior Vice President
Amy Broidrick
President, Chief Strategy and Operating Officer